Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 3Lymphoid 2Gynecologic 2Genitourinary 2Gastrointestinal 2Thoracic 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 1409Fluorouracil 1298Capecitabine 1085Gemcitabine 1042Leucovorin 928Irinotecan 815Bevacizumab 803Cisplatin 666Radiotherapy 535Cetuximab 469pembrolizumab 428Paclitaxel 389Nivolumab 336130-nm albumin-bound paclitaxel 322Drug Therapy 314Docetaxel 286S 1 (combination) 273Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 209Surgical Procedures, Operative 203tislelizumab 202Radiosurgery 202lenvatinib 201apatinib 198Carboplatin 186Magnetic Resonance Spectroscopy 181regorafenib 180

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × eprenetapopt × Gastrointestinal × Clear all
NCT04383938 2025-05-13

Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

Aprea Therapeutics

Phase 1/2 Completed
40 enrolled 11 charts
GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT02999893 2021-12-13

APROC

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Terminated
5 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡